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Abstract KOR-3, also known as ORL-1, is a member of the
opioid receptor family, encoding the murine receptor for
orphanin FQ/nociceptin. In the current studies we have identified
five different splice variants of KOR-3 in mouse brain, three of
which have not been previously reported. In addition to variants
with a 15 bp deletion at the 3P-end of the first coding exon (KOR-
3d) and an 81 bp insertion between the second and third coding
exons (KOR-3e), three new variants with insertions of 34 (KOR-
3a), 98 (KOR-3b), and 139 bp (KOR-3c) between the first and
second coding exons have been obtained. The expression of the
three variants in mouse brain varies markedly among brain
regions with a distribution which is quite distinct from KOR-3
itself. Of greatest interest was the presence of high levels of
KOR-3a in the striatum, a region with no demonstrable KOR-3,
and in the cortex. KOR-3c was seen in the periaqueductal gray
and hypothalamus, regions where KOR-3 predominated. The
brainstem had similar levels of KOR-3, KOR-3a, and KOR-3d.
In contrast, KOR-3d was most prominent in the cerebellum.
KOR-3b levels were very low throughout.
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1. Introduction
A novel member of the opioid receptor family has been
recently cloned from human (ORL-1), mouse (KOR-3) and
other species [1^8]. The murine KOR-3 gene has been cloned
and sequenced and contains ¢ve exons separated by four in-
trons [4]. Although structurally homologous with the cloned
traditional opioid receptors, the receptor encoded by KOR-3
has low a⁄nity for most opioids and opioid peptides. The
recent discovery of the endogenous ligand for this receptor,
the neuropeptide orphanin FQ [9]/nociceptin [10] (OFQ/N)
has provided important insights into the functional signi¢-
cance of this receptor. OFQ/N is intimately involved with
pain perception, but its actions are complex. Initially, it was
reported to be hyperalgesic [9,10] and low doses reverse the
actions of opioids [11^16]. Yet, OFQ/N is also an analgesic
[14,17^20].
The complex pharmacology of OFQ/N and its analogs,
along with other studies, has raised the possibility of multiple
OFQ/N receptors. Radiolabeled OFQ/N binding to brain ho-
mogenates [21] is quite distinct from that to the cloned recep-
tor [9,22] and is consistent with binding site heterogeneity in
the brain. Antisense mapping the three coding exons of the
receptor encoded by KOR-3 also raised the question of alter-
native splicing [1,2,16,17,23]. Antisense probes targeting the
¢rst coding exon blocked OFQ/N hyperalgesia, but not anal-
gesia, while other probes targeting the second and third exons
blocked analgesia and not hyperalgesia. The second and third
coding exons, but not the ¢rst, also have been implicated in
kappa3 analgesia. These observations raised the possibility
that the kappa3 receptor and KOR-3 might result from alter-
native splicing of the same gene [4]. Two alternatively spliced
variants have been reported, including a rat variant (XOR1L)
which contains a 28 amino acid insertion between the second
and third coding exons [24] and another with a 15 base dele-
tion corresponding to Tyr71^Arg75 in the ¢rst intracellular
loop [25]. Here we report the identi¢cation and regional ex-
pression of additional KOR-3/ORL-1 variants isolated from
mouse brain.
2. Materials and methods
2.1. Identi¢cation of alternative splicing variants by RT-PCR
A sense (5P-TGCC TTC CTG CCC CTT GGA C-3P ; positions
419^438) and an antisense primer (5P-CCC AGA AGG ATG TCT
GTG CCC-3P ; position 610^630) based upon the nucleotide sequence
of the mouse KOR-3 clone (GenBank accession number U09621)
were used to amplify cDNA fragments using PCR. The template
was ¢rst-strand cDNA reverse transcribed with random hexamers
from C57BL/6 mouse brain total RNA prepared as described [26].
Multiple bands were obtained by PCR, isolated, subcloned and se-
quenced in both directions. Four KOR-3-related clones were identi-
¢ed.
2.2. cDNA library screening
We screened a C57BL/6 mouse brain VZAP cDNA library with a
32P-labeled 1.1 kb fragment containing the full length KOR-3 coding
region at high stringency, identifying 32 positives. Three contained a
34 bp insertion (KOR-3a), one had a 98 bp insertion (KOR-3b), one
had a 139 bp insertion (KOR-3c) and another had an 81 bp insertion
between coding exons 2 and 3 (KOR-3e). We sequenced KOR-3a and
KOR-3c clones of approximately 2.9 kb and a 1.2 kb clone of KOR-
3b. We did not observe any clones with the 15 bp deletion in the ¢rst
exon in these screens.
2.3. Northern blot analysis
Polyadenylated RNAs were isolated from mouse total RNAs using
oligo(dT) chromatography (Pharmacia, Piscataway, NJ) as described
[2]. Northern blotting followed the protocol for GeneScreen Plus
membranes (New England Nuclear, Boston, MA). Probes for KOR-
3a (5P-GGT GTG CCT GCT GTC TCC AGT TCC CCT CAA TGC
CCT CCC AGC TGA GGA-3P) and KOR-3b/KOR-3c (5P-CCT CAG
TCT CTC TTA AGA CTC CTC TCA GAG GGT TTT CAG GGC
ACT GCC-3P) were 5P-end 32P-labeled by T4 polynucleotide kinase. A
32P-labeled 1.1 kb fragment containing the full length of the KOR-3
coding region was generated by PCR with appropriate primers.
2.4. Analysis of KOR-3a, KOR-3b and KOR-3c expression in various
brain regions
Total RNAs from various C57BL/6 mouse brain regions were ex-
tracted and reverse transcribed using random hexamers. Two primers
were designed from the nucleotide sequence of mouse KOR-3/ORL-1
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receptor at positions 486^505 (sense primer, 5P-TCC TGG GGA ACT
GCC TCG TC-3P) and 610^630 (antisense primer, 5P-CCC AGA
AGG ATG TCT GTG CCC-3P) and used in sequential PCR reactions
with the ¢rst-strand cDNAs as templates. The predicted sizes of the
ampli¢ed cDNA fragments for KOR-3, KOR-3a, KOR-3b and KOR-
3c are 145 bp, 179 bp, 232 bp and 284 bp, respectively. The PCR
products were then separated by 1.5% agarose gel, transferred on
GeneScreen Plus membranes and hybridized with a 32P-labeled 107
bp fragment of the coding exon 2 generated by PCR (Fig. 1). The
RNA loading in the RT-PCR reactions was estimated by parallel
PCR with L2-microglobulin primers (Clontech).
3. Results
3.1. cDNA cloning of alternative splicing variants of
KOR-3 gene
To look for variants di¡ering in the region between the ¢rst
and second coding exons, we performed RT-PCR using an
upstream primer in the ¢rst coding exon and a downstream
primer in the second. This led to the identi¢cation of four
splice variants. Three had insertions between the ¢rst and
second coding exons (Fig. 1) while the fourth had a 15 bp
deletion at the 3P-end of the ¢rst coding exon, corresponding
to a variant cloned from lymphocytes [25]. We then isolated
full length cDNAs containing the 34 bp (KOR-3a), the 98 bp
(KOR-3b) and the 139 bp (KOR-3c) insertions by screening a
mouse brain cDNA library with a full length KOR-3 probe.
The sequences of the new cDNAs were identical to that of
the KOR-3 cDNA except for the insertions. The insertion
sequences of KOR-3a, KOR-3b and KOR-3c were aligned
to the intron between the ¢rst and second coding exons of
the KOR-3 gene [4] and the 81 bp insertion in KOR-3e to
the intron between the second and third coding exons (Fig. 2).
All of the splice sites were in agreement with the GT/AG
rule.
3.2. Northern analysis of KOR-3 and its splice variants
We next used Northern blot analysis to investigate the full
length transcripts of the variants obtained from whole brain
mRNAs (Fig. 3). The KOR-3a probe hybridized a major tran-
script with a size of approximately 2.9 kb, with another
smaller sized band of lower abundance. Since the 139 bp in-
sertion in KOR-3c contains the 98 bp in KOR-3b, there is no
speci¢c probe for the KOR-3b. We therefore used a 48 bp
probe derived from the 98 bp to detect both the KOR-3b
and KOR-3c expression. This probe hybridized a major tran-
script with a size of approximately 3.4 kb, which was similar
to that probed by the KOR-3 probe. The relative abundance
of the transcripts revealed by the KOR-3a probe was much
higher than that by the KOR-3b and KOR-3c probe,
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Fig. 1. Schematic of KOR-3 gene and alternative splicing. Exons
and introns are indicated by open boxes and horizontal lines, re-
spectively. Mini-exon 1a with 34 bp is shown by the solid box with
horizontal lines, mini-exon 1b with 98 bp by the solid box with di-
agonal lines and mini-exon 1c with 139 bp (including mini-exon 98
bp) by a solid black box and box 1b. The shaded area of exon 1
represents the deletion originally reported in lymphocytes [25] which
we also saw in brain. Arrows represent the primers used in RT-
PCR reaction to clone the splicing variants. The short heavy line
over exon 2 denotes the probe used in Southern blotting to detect
expression of KOR-3 gene splicing variants.
Fig. 2. Insertion sequences of KOR-3a,b,c and e. Insertion sequences of (a) KOR-3a, (b) KOR-3b and KOR-3c, (c) KOR-3e. Intronic se-
quences are in lower case and exons are given in upper case. The complete KOR-3a, KOR-3b and KOR-3c cDNA sequences have been sub-
mitted to GenBank under accession numbers AF043276, AF043277 and AF043278, respectively. Base numbers for genomic and cDNA sequen-
ces are based upon intron 2 of the KOR-3 gene (GenBank accession number U32939) and KOR-3 cDNA (accession number U09421)
sequences. The splicing junctions are indicated by arrows. In (b) arrows indicate the splicing junctions for KOR-3c and KOR-3b.
Y. Pan et al./FEBS Letters 435 (1998) 65^6866
although it was less abundant than that by the KOR-3 probe.
We saw no bands with the KOR-3e probe.
3.3. Regional expression of the splice variants
We next examined the regional distribution of the variants
using RT-PCR and Southern blotting. Four major bands were
obtained with di¡erent intensities among the various regions
(Fig. 4). The sizes of the four bands from the lower to the
higher matched those of the 15 bp deletion (clone D), KOR-3,
34 bp insertion (clone A) and 139 bp insertion (clone C),
respectively. To con¢rm that the ampli¢ed bands correspond
to the KOR-3 splice variants, each band was extracted from
the agarose gel, subcloned into the Bluescript vector and se-
quenced. In all cases, the sequences of the bands were identi-
cal to those of the variant clones. The relative abundance in
whole brain of KOR-3 and its variants was similar to that
seen with Northern blotting: KOR-3sKOR-3asKOR-3c.
Although KOR-3b expression was not seen in the initial
PCR and the blotting, the KOR-3b fragment was ampli¢ed
by a second round PCR using the gel extracts corresponding
to the KOR-3b from the ¢rst PCR as templates (data not
shown). This implies a very low level of expression of KOR-
3b in brain.
Among the regions examined, the KOR-3 transcript was
most abundant in the hypothalamus and periaqueductal
gray (PAG), while the cortex, striatum and brainstem had
higher levels of the KOR-3a. The KOR-3c was highly ex-
pressed in PAG and hypothalamus and the KOR-3d in cer-
ebellum, hypothalamus and brainstem. Lower levels of KOR-
3c were seen in the cortex, PAG and thalamus. Interestingly,
the only major variant expressed in the striatum was KOR-3a.
This di¡erential expression of the variants among the regions
implies region-speci¢c splicing and argues strongly for their
functional relevance.
4. Discussion
In addition to the variants reported earlier, the current
studies have identi¢ed a number of additional splice variants
of KOR-3/ORL-1. The insertions observed in the new var-
iants correspond to the region between TM1 and the ¢rst
intracellular loop, a splice site common among all the opioid
receptors. Similar splicing variants with insertions between
exons one and two have been identi¢ed in mouse delta recep-
tor (DOR-1) gene [27] and the mu (MOR-1) gene (Y.-X. Pan,
J. Xu and G.W. Pasternak, unpublished observations). The
presence of such a large number of variants underscores the
extensive alternative splicing at this location. The splicing be-
comes even more interesting in view of the di¡erential region-
al expression of these variants. Perhaps the best example is the
striatum, which has been reported to be devoid of ORL-1
message and OFQ/N receptors. We also saw little evidence
for any appreciable levels of KOR-3/ORL-1 in this region,
in contrast to the high expression of KOR-3a. This regional
speci¢c mRNA processing is quite interesting.
Identi¢cation of multiple KOR-3 variants with insertions
between the ¢rst and second coding exons implies extensive
alternative splicing at this location. G triplet repeats may play
a role in exon-intron border selection and in alternative exon
determination [28] and the 34 bp insertion sequence in KOR-
3a contains three G triplets. Although the role of the G trip-
lets within the 34 bp in KOR-3a splicing has not been estab-
lished, it may be interesting to determine whether speci¢c
factors capable of binding the G triplets are di¡erentially ex-
pressed among brain regions. It has also been reported that
many alternatively spliced exons contain GAR repeats, where
R is a purine, which have been referred to as exonic splicing
enhancers or ESEs [29]. SRp55 is a speci¢c ESE binding pro-
tein. Thus, the presence of multiple GAR repeats in the in-
sertion sequences of both the KOR-3b and the KOR-3c might
contribute to the regional expression of the KOR-3b and the
KOR-3c.
The KOR-3e appears to be an intron-retention variant and
is very similar to a rat variant [24]. Unlike the murine version,
which contains a termination codon which would lead to a
truncated receptor lacking the last three transmembrane re-
gions, the published rat version does not appear to have the
termination codon.
Translation of the cDNAs using the start codon AUG of
KOR-3 results in early termination either at the mini-exon
insertion (KOR-3c) or shortly after the insertion (KOR-3a
and KOR-3b). Yet, in preliminary studies the expressed full
length clones containing these insertions bind the kappa3 lig-
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Fig. 3. Northern blotting of KOR-3 and its splice variants. Poly-
(A) RNA isolation and Northern blotting are described in Section
2. Lanes were loaded with 15 Wg of poly(A) RNA.
Fig. 4. Regional distribution of the alternatively spliced variants.
Total RNAs were extracted from the indicated brain regions and
used in the RT reactions with a sense primer targeted close to 3P of
the coding exon 1 and an antisense primer near to 5P of the coding
exon 2 (see arrows, Fig. 1). L2-Microglobulin (L2MG) served as an
internal control for the regions. The PCR products were assayed by
Southern blot.
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and [3H]naloxone benzoylhydrazone quite well (unpublished
observations). Although the truncated protein may retain high
a⁄nity for the ligands, this seems unlikely. Alternative expla-
nations include an alternative start codon which would be in
frame with the second and third coding exons or possibly
RNA editing.
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